Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 02/04/2021

Summary

Erik T. Engelson, a Director and officer listed as "President and Chief Executive" of Lucira Health, Inc. [ LHDX ], reports a grant on 02/04/2021 of a Stock Option (right to buy) for 173,937 shares of Common Stock at $ 17, expiring 02/03/2031. Under the footnote, 25% of the option shares vest on the first anniversary of the grant date and 1/48th vest monthly over the following 36 months. The form was signed by /s/ Dan George, Attorney-in-Fact for Erik T. Engelson, on 02/08/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Engelson Erik T. (Last) (First) (Middle) 1412 62ND STREET (Street) EMERYVILLE CA 94608 (City) (State) (Zip) | Engelson Erik T. | (Last) | (First) | (Middle) | 1412 62ND STREET | EMERYVILLE | CA | 94608 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Lucira Health, Inc. [ LHDX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) President and Chief Executive | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | President and Chief Executive
3. Date of Earliest Transaction
 (Month/Day/Year) 02/04/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 17 | 02/04/2021 | A | 173,937 | (1) | 02/03/2031 | Common Stock | 173,937 | $ 0.00 | 173,937 | D
Explanation of Responses:
1. 25% of the shares underlying this option shall vest on the first annual anniversary of the grant date and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
Remarks:
/s/ Dan George, Attorney-in-Fact for Erik T. Engelson | 02/08/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_LHDX_4_filed2021-02-08_0001209191-21-008568.xml

Size

15,581 bytes

SHA-256

0d447499c71dcf74d29ff456f120d77f47b1c937fba5ab7e9776dff6c31a3ce6

Our copy

SEC_LHDX_4_filed2021-02-08_0001209191-21-008568.xml

Original

www.sec.gov